-
Foretinib: From Kinase Signal to Cell Fate
2026-09-08
Foretinib (GSK1363089) is a multikinase research tool for connecting Met and VEGFR signaling with distinct cancer-cell response phenotypes. This guide shows how to distinguish growth arrest, cell death, motility loss, and metastatic behavior in a more informative experimental workflow.
-
Macrophage EP4 Loss Accelerates Atherosclerosis
2026-09-08
The reference study identifies macrophage EP4 deficiency as a driver of atherosclerosis progression, linking receptor loss to CD36-dependent lipid uptake, foam-cell formation, and M1 polarization. Its combination of a myeloid-specific knockout model, oxLDL-stimulated macrophages, transcriptomics, proteomics, qPCR, and immunoblotting provides a mechanistic framework for interpreting how inflammatory and lipid-handling programs converge in plaque disease.
-
NF-κB/miR-202-5p/HMGB2 in Septic AKI
2026-09-07
The reference study identifies an inducible NF-κB/miR-202-5p/HMGB2 feedback circuit that limits renal inflammation and tubular cell death during septic acute kidney injury. Its combined in vitro and in vivo evidence links NF-κB activation to a protective microRNA response, while positioning HMGB2 as a target that may sustain inflammatory signaling.
-
Palbociclib (PD0332991) Workflow for Cancer Assays
2026-09-07
Build more interpretable cell-cycle and oncology assays with Palbociclib (PD0332991) Isethionate, from concentration-response screening to mechanistic validation. The workflow separates cytostatic G0/G1 arrest from apoptosis and extends the ERCC1–p53 DNA-repair findings of a lung cancer study into carefully controlled assay designs.
-
SNORA38B Rewires NSCLC Immunotherapy Response
2026-09-05
The reference study identifies SNORA38B as an oncogenic small nucleolar RNA that links tumor-cell signaling to immune suppression in non-small cell lung cancer. Its mechanistic and in vivo evidence supports SNORA38B inhibition as a strategy for remodeling the tumor microenvironment and improving immune checkpoint blockade responses.
-
Cabozantinib (XL184) for Adaptive RCC Signaling
2026-09-04
Cabozantinib (XL184) enables side-by-side analysis of acute kinase suppression, chronic phosphoproteomic adaptation, angiogenesis, and tumor-cell motility. This workflow translates renal cell carcinoma findings into practical assay designs while separating biochemical potency from cellular response.
-
L1023 Anti-Cancer Compound Library: STING Logic
2026-09-04
Explore how the L1023 Anti-Cancer Compound Library can support mechanism-aware cancer research, using new STING structural biology to improve hit interpretation. This article connects pathway-level screening with orthogonal assays for more defensible drug-discovery decisions.
-
Cisplatin (CDDP): Applied Cancer Research Workflows
2026-09-03
Build reproducible Cisplatin workflows for viability, apoptosis, DNA-damage, and chemotherapy resistance studies. A TNBC combination strategy with tabersonine shows how CDDP can also serve as a mechanistic benchmark for testing chemosensitization and EMT-related phenotypes.
-
GDC-0994 ERK1/2 Inhibitor Workflow
2026-09-03
GDC-0994 provides a practical way to test whether ERK1/2 activity drives mutant RAS/BRAF phenotypes or estrogen-associated cholestatic injury. This workflow combines target-engagement assays, rescue experiments, bile-flow measurements, and troubleshooting guidance for more defensible pathway conclusions.
-
OSMI-1: From OGT Inhibition to Ferroptosis
2026-09-02
Explore how OSMI-1, a cell-permeable O-GlcNAc transferase inhibitor, can translate O-GlcNAcylation research into mechanistic ferroptosis assays. This article connects OGT inhibition with the HUWE1–TfR1 pathway while defining essential controls, limitations, and disease-model boundaries.
-
Quizartinib (AC220) Workflows for FLT3 Research
2026-09-02
Build cleaner FLT3 inhibition experiments with Quizartinib (AC220), from biochemical target engagement to AML cell assays and xenograft studies. The workflow combines selective pharmacology with genetic controls, orthogonal readouts, and troubleshooting strategies for resistance and variable exposure.
-
Cediranib (AZD2171) In Vitro Workflow
2026-09-01
Build a more informative angiogenesis assay with Cediranib (AZD2171), linking VEGFR pathway suppression to endothelial behavior and distinct growth-versus-death outcomes. This workflow combines dose response, pathway verification, and orthogonal viability measurements for stronger cancer research conclusions.
-
Plerixafor (AMD3100) for CXCR4 Research
2026-09-01
Plerixafor (AMD3100) gives researchers a reversible way to interrogate CXCL12/CXCR4 signaling across tumor, blood, and bone-marrow models. Its value is especially strong when receptor blockade must be paired with spatial imaging, chemotaxis assays, or cell-mobilization readouts rather than used as a single endpoint.
-
MCC950 sodium in NLRP3 Research Workflows
2026-08-31
MCC950 sodium, also known as CRID3 sodium salt, enables selective dissection of NLRP3 signaling across macrophage, peripheral immune-cell, and neuroinflammation models. This workflow-focused guide connects cytokine assays with the reference study’s astrocyte-phenotype findings and provides practical optimization strategies.
-
SERCA–ER Stress in HSC Mobilization
2026-08-31
Li and colleagues identify SERCA inhibition as an upstream route for enhancing hematopoietic stem cell mobilization. Using BHQ, in vivo mobilization assays, cell-based phenotyping, and pathway validation, the study links ER stress to reduced CXCR4 surface expression through the CaMKII–STAT3 axis.